Why is Nuvation Bio (NUVB) stock up today?

Nuvation Bio shares climbed roughly 7.8% today to $6.25 — hitting an intraday high of $6.52 — after the company released encouraging long-term data from its Phase 2 trial of safusidenib, an experimental drug targeting IDH1-mutant glioma (a type of brain tumor caused by a specific gene mutation). The updated readout showed a confirmed objective response rate of 52% and a 36-month progression-free survival rate of 79% with nearly 40 months of follow-up, results the company described as showing 'durable' efficacy.

Alongside the data, Nuvation Bio announced an expansion of the safusidenib clinical program, adding two new studies to explore a broader spectrum of IDH1-mutant glioma patients. The company also said a new Phase 3 study will evaluate safusidenib in newly diagnosed Grade 2 glioma patients outside the U.S. These program expansions signal increased confidence in the drug's potential scope. Wall Street analysts took note: RBC highlighted a roughly $3 billion commercial opportunity in the brain cancer indication, while Wedbush said the data support a broader glioma opportunity.

The broader market provided a mixed backdrop — the S&P 500 was down 0.19% and the Nasdaq (QQQ) was up 0.10% on the day — meaning NUVB's surge was driven almost entirely by company-specific news rather than sector or market tailwinds. In fact, the healthcare sector as a whole fell later in the afternoon, making Nuvation Bio's gain stand out further.

As of the close, Nuvation Bio carries a market capitalization of approximately $2.17 billion. The company has no revenues from commercial products yet — last quarter's $83.2 million in revenue and EPS of $0.038 reflect its clinical-stage status. The stock's move today reflects the market pricing in improved probability that safusidenib advances toward a broader commercial launch.